XSTO
CLS B
Market cap5mUSD
Oct 07, Last price
1.79SEK
1D
0.56%
1Q
-47.35%
Jan 2017
-99.91%
IPO
-99.85%
Name
Clinical Laserthermia Systems AB
Chart & performance
P/E
—
P/S
3.22
EPS
—
Div yield, %
—
Shrs. gr., 5y
159.27%
Rev. gr., 5y
67.36%
Revenues
17m
-6.90%
Net income
-42m
L-12.62%
CFO
-33m
L-41.19%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Clinical Laserthermia Systems AB (publ) engages in the development of treatment tools for diseased tissue under the TRANBERG brand in Sweden. It offers TRANBERG, a thermal therapy system designed to deliver laser energy to heat the target tissue. The company also provides mobile laser unit, a controlling component with a wavelength of 1064 nanometers that provides multiple options to control treatment. In addition, it offers various gauge laser applicators and introducers, as well as provides temperature and treatment monitoring devices. Clinical Laserthermia Systems AB (publ) was incorporated in 2006 and is headquartered in Lund, Sweden.
Key people
Chairman of the Board · since 2013
Lars-Erik Eriksson
Chief Executive Officer, Director
Michael Magnani
Managing Director of CLA Americas Inc. · since 2019
Stephan Dymling
Chief Technology Officer · since 2011
Dan J. Mogren
Director of Marketing & Sales
Gunilla Savring
Head of Investor Relations
Stefan Astrom
Head of Clinical Development
Mats Ekelund
Chief Medical Officer · since 2017
Ingmar Malm
Director of Quality Assurance
Karin Peterson
Chief Product Officer · since 2016
Rolf Kiessling
Director · since 2013
Karl-Goran Tranberg
Director
Headquarters & legal address
Scheelevägen 2
Lund, M 223 81
SE
Lund, M 223 81
SE
Address
Scheelevagen 2
Lund, M 223 81
SE
Lund, M 223 81
SE
Valuation
Title SEK in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||